- Membership & Community
-
Publications & News
- Journals
-
Newsroom
-
The Physiologist Magazine
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- In Depth
-
Mentoring Forum
- Net Worth
- Take Care
- You … In Charge
- Work. It. Out.
- Working Off-site
- Location, Location, Location?
- Student Support
- Progressing to Postdoc
- Relationship Building
- Let’s Get It Started
- What Do We Value?
- It’s a Postdoc Life
- Coronavirus Contributions
- Creative Communications
- Selection Process
- Conference Connections
- Postdoc Appreciation
- Research Rewards
- Focus on Teaching
- Industry Insights
- Balance Beam
- Post Postdoc
- If You Build It
- Talk It Through
- Forward Bound
- I’ve Earned My PhD. Now What?
- University Life
- Tips for Trainees
- Time Travel
- Policy IQ
- Publish with Polish
- Under the Microscope
- Mentoring Q&A
- The Physiologist Magazine Readers Survey
- Evolution
- Baseline by Scott Steen, CAE, FASAE
- Find Us on Social Media
-
The Physiologist Magazine
-
Professional Development
-
Meetings & Events
-
American Physiology Summit
- #APS2024 Overview
- Abstracts
- Awards at the Summit
- Award Lectures
- Career Networking Lunch Form
- Dates and Deadlines
- Hotel Information
- Industry Partners
- Keynote Speaker—Brian Kobilka, MD
- Keynote Speaker—Jessica Meir, PhD
- Mobile App
- NIH and NSF Program Officer Panel Discussion Form
- Off-site Summit Meetups
- Physical Poster Information
- PhysioHub
- Pre-Summit Events
- Registration
- Section & Group Banquet Tickets
- Speaker Audiovisual Instructions
- Summit FAQs
- Summit Newsroom
- Summit Store
- Travel & Transportation
- Undergraduate Program Book
- Liability Waiver
- Summit Call for Proposals
- Industry Partners
- Martin Frank Diversity Travel Award Orientation Agenda
- Martin Frank Diversity Travel Award Networking Luncheon Agenda
- Women in Physiology Networking Event Agenda
-
2023
- APS 2023 Call for Proposals
- Women in Physiology Networking Mixer Registration
- Career Networking Lunch Form
- NIH Program Officer Panel Discussion Form
- Shocklogic Test
- Team 2023 Task Force
- Shaping the Summit
- Schedule at a Glance
- Pre-Summit Events
- Pre-Summit Center for Physiology Education Workshop Registration
- Section & Groups Banquet Tickets
- Summit Store
- Pre-Summit Center for Physiology Education Workshop
- Press Registration
- Meet the Organizers
- Keynote Speaker—Terrie Williams, PhD
- Keynote Speaker—David Julius, PhD
- Industry Workshop Information
- Important Dates and Deadlines
- Hotel Information
- Game Changers
- Distinguished Lecturers
- Building APS 2023
- Awards at the Summit
- 2023 Summit Information
- American Physiology Summit Program
- 2023 Summit Newsroom
- Scientific Integrity Policy
- From Concept to Classroom
- Webinars
- Related Meetings
- Future APS Conferences
-
Past APS Conferences
- APS Institute on Teaching and Learning
- Integrative Physiology of Exercise
- Seventeenth International Conference on Endothelin (ET-17)
- New Trends in Sex and Gender Medicine
- APS Institute on Teaching and Learning (2022)
- Control of Renal Function in Health and Disease Conference
- Comparative Physiology: From Organisms to Omics in an Uncertain World
- Conference Policies
-
American Physiology Summit
- Awards
-
Career & Professional Development
-
Career Gateway
-
Resources
- Transcript—Leading Through Conflict and Difficult Conversations
- Transcript—Managing Conflict with Colleagues
- Transcript—Leading a Team Through Conflict
- Transcript—Providing Difficult Feedback
- Transcript—Team Dynamics and Culture Primer
- Transcript—Building a Team
- Transcript—Leading a Team Assigned to You
- Transcript—Creating a Team Culture
-
Resources
- Career Navigator
- Center for Physiology Education
- Job Board
- Mentoring
- APS Graduate Physiology & Biomedical Science Catalog
-
Career Gateway
-
Meetings & Events
-
Advocacy & Resources
- Policy Areas
-
Resources
- Researcher Resources
- Educator Resources
- Trainee Resources
- Student Resources
-
APS Graduate Physiology & Biomedical Science Catalog
- Augusta University
- Des Moines University
- East Tennessee State University
- George Washington University
- Louisiana State University Health Sciences Center Shreveport
- Mayo Clinic Graduate School of Biomedical Sciences—Biomedical Engineering & Physiology
- Medical College of Wisconsin
- Michigan State University
- New York Medical College
- Nova Southeastern University
- Pennsylvania State University
- Saint Louis University
- Texas A&M University
- Texas A&M University Medical Physiology
- Stony Brook University
- The University of Iowa
- The University of Mississippi Medical Center
- University of Alabama at Birmingham
- University at Buffalo
- University of Colorado
- University of Delaware
- University of Florida
- University of Louisville
- University of Michigan
- University of Minnesota
- University of Missouri-Biomedical Sciences
- University of Nebraska Medical Center
- University of Oregon
- University of South Carolina School of Medicine
- University of Tennessee Health Science Center (UTHSC)
- University of Texas Health Science Center
- Virginia Commonwealth University
- Wayne State University
- Wake Forest University
- Physiology Department Catalog Submission Form
- Career Gateway
- Diversity, Equity & Inclusion
- Advocacy
- About APS
Review encourages medical personnel to develop personalized treatment based on patient’s pathophysiology
Rockville, Md. (June 11, 2020)—A new review details three distinct phases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and urges medical professionals to consider an individualized treatment approach based on the disease phases and each patient’s symptoms. The review is published ahead of print in Physiological Reviews.
SARS-CoV-2, the novel coronavirus that causes COVID-19, is transmitted through droplets expelled from an infected person’s nose or mouth when they cough, sneeze or, in some cases, talk. Three distinct phases of COVID-19 infection have been observed in some people who test positive for the disease and have variable degrees of symptoms. Each phase is characterized by a different type of pathophysiological interaction with the virus.
During the early infection phase (Phase 1), the virus multiplies inside the body and is likely to cause mild symptoms that may be confused with a common cold or flu. The second phase is the pulmonary phase (Phase 2), when the immune system becomes strongly affected by infection and leads to primarily respiratory symptoms such as persistent cough, shortness of breath and low oxygen levels. Problems with blood clotting—especially with the formation of blood clots—may be predominant in Phase 2. The third, hyperinflammatory phase (Phase 3), occurs when a hyperactivated immune system may cause injury to the heart, kidneys and other organs. A “cytokine storm”—where the body attacks its own tissues—may occur in this phase. While there may be overlap among the three stages of disease, the review authors stress that it is crucial to recognize each stage in order to tailor treatment to the patient.
Many of the drugs used to treat people with COVID-19 are still being investigated for safety and effectiveness. The reviewers encourage researchers to evaluate these experimental treatments based on the specific disease phase they are being prescribed for, along with what is happening in the body as COVID-19 progresses. Drawing on experience treating patients in Italy, one of the hardest-hit countries during the earliest days of the pandemic, the researchers suggest medical professionals choose a personalized treatment plan with the following medications and treatments:
- Plasma containing antibodies from recovered COVID-19 patients (i.e., hyperimmune plasma), which has been found to reduce the amount of live virus (viral load) in the early infection phase.
- Antiviral drugs, including remdesivir, which have helped interrupt viral replication in Phase 1 and may continue to be beneficial in Phase 2.
- Tissue plasminogen activator (tPA). A drug used to treat stroke, tPA breaks up blood clots that may occur during Phase 2.
- Inflammation-fighting medications, including corticosteroids, tocilizumab and sarilumab. These may help reduce system-wide inflammation in Phases 2 and 3.
- The anticoagulant (anti-clotting drug) heparin is important during any stage of the disease to prevent blood clots in blood vessels and capillaries (micro- and macro-vascular thrombosis).
Although to date, there are no drugs proven to treat COVID-19, research is progressing rapidly. “We are now entering a new era of the pandemic, with many ongoing [randomized controlled trials] aimed at identifying patient-tailored drugs, and drugs better suited to the specific phase of the disease with improved precision,” the authors wrote. The scientific community is “making a tremendous effort to support an unprecedented number of pathophysiological studies and clinical trials to face this highly unexpected pandemic.”
Read the full article, “SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty,” published ahead of print in Physiological Reviews.
NOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or call 301.634.7314. Find more research highlights in our News Room.
Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents 9,000 members and publishes 16 peer-reviewed journals with a worldwide readership.
Related Content
- Nobel Laureate and NASA Astronaut to Speak at American Physiology Summit
- Researchers Identify How HIV/Hepatitis Drug Harms the Kidneys
- High-intensity Aerobic Exercise Helps Prevent Menopause-related Muscle Power Loss
- Women with Long COVID May Develop High Blood Pressure
- Teaching Section Resources
- Mitochondrial Changes Linked to High Blood Pressure in Pregnancy
- Alcohol Abuse Increases Sensitivity of Coronavirus Infection
Contact Us
For questions, comments or to share your story ideas, email us or call 301.634.7314.